Posted by Michael Wonder on 05 Nov 2024
Electra Therapeutics receives FDA fast track designation for ELA026 in secondary haemophagocytic lymphohistiocytosis
4 November 2024 - Electra Therapeutics today announced that the US FDA has granted fast track designation for ELA026 for the treatment of secondary haemophagocytic lymphohistiocytosis.
ELA026, a first in class antibody therapy targeting signal regulatory proteins , is a novel approach to treat secondary haemophagocytic lymphohistiocytosis, a rare, life threatening disease for which there is no approved treatment.
